Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Indivior PLC
Indivior PLC
Activities:
Research & Development
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Design & Build
Indivior awards BES £4m design project
The cleanroom construction company has been chosen to create a new production facility for the opioid addiction treatment specialist
Design & Build
Boulting Environmental Services completes Indivior R&D facility
The UK-based cleanroom and lab design and construction company has completed the construction phase of a £13 million project for global pharmaceutical business Indivior, a specialist in the treatment of opioid addiction
Research & Development
New schizophrenia drug may improve patient compliance
RBP-7000, new pipeline novel sustained-release drug by Indivior, showed patients “stable or improved” throughout test period
Subscribe now